DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zonegran (Zonisamide) - Summary

 
 



ZONEGRAN SUMMARY

ZONEGRAN® (zonisamide) capsules Rx Only

ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents.

ZONEGRAN is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.


See all Zonegran indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zonegran (Zonisamide)

How stress increases seizures for patients with epilepsy
Source: Epilepsy News From Medical News Today [2016.06.15]
Epilepsy changes the way the brain responds to stress, researchers find, which may explain why stress can increase seizure frequency.

Childhood Vaccinations Rarely Spur Seizures, Study Finds
Source: MedicineNet Tetanus Specialty [2016.06.06]
Title: Childhood Vaccinations Rarely Spur Seizures, Study Finds
Category: Health News
Created: 6/6/2016 12:00:00 AM
Last Editorial Review: 6/6/2016 12:00:00 AM

Breast cancer drug found to reduce seizures
Source: Epilepsy News From Medical News Today [2016.05.13]
Findings from animal study could lead to improved seizure treatment in humans.

Algorithms that can predict epileptic seizures
Source: Epilepsy News From Medical News Today [2016.05.12]
Computer scientists and mathematicians at the CEU Cardenal Herrera University in Valencia have developed a prediction model that can warn epileptic sufferers of an upcoming seizure with 20 minutes...

Brain signals between seizures may explain memory problems in patients with epilepsy
Source: Epilepsy News From Medical News Today [2016.04.26]
Study suggests how future devices might prevent cognitive deficits. Between seizures and continually, brain cells in epileptic patients send signals that make "empty memories," perhaps explaining...

more news >>

Published Studies Related to Zonegran (Zonisamide)

Zonisamide: a review of its use in the management of adults with partial seizures. [2013]
Oral zonisamide (Zonegran(®)) is a benzisoxazole derivative chemically unrelated to other antiepileptic agents. It is indicated in the EU as monotherapy in the treatment of partial seizures, with or without secondary generalization, in adults with newly diagnosed epilepsy and as adjunctive therapy to other antiepileptic drugs (AEDs) in the treatment of adults with partial seizures, with or without secondary generalization...

The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial. [2013]
CONCLUSION: Zonisamide as an adjuvant treatment is tolerated well and markedly

Zonisamide: its pharmacology, efficacy and safety in clinical trials. [2012]
Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for adjunctive treatment of partial seizures in adults, and in Europe as monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy...

Assessment of treatment algorithms including amantadine, metformin, and zonisamide for the prevention of weight gain with olanzapine: a randomized controlled open-label study. [2011.05.17]
CONCLUSIONS: Pooled treatment algorithm results were not significantly different from olanzapine monotherapy in mitigating weight gain. However, participants who received treatment with metformin with possible progression to amantadine and then zonisamide had significantly less mean weight gain than participants treated with olanzapine alone. Progression of some participants through the algorithm indicated that a single therapy solution may not be adequate for every patient. Patients treated with olanzapine should receive regular weight monitoring. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00401973. (c) Copyright 2011 Physicians Postgraduate Press, Inc.

Efficacy and safety of adjunctive zonisamide in adult patients with refractory partial-onset epilepsy: a randomized, double-blind, placebo-controlled trial. [2011]
BACKGROUND AND OBJECTIVE: Clinical studies have reported that zonisamide is effective for a wide range of seizure types, including refractory partial-onset seizures. However, there have been no reported studies of the efficacy of zonisamide in the Chinese population to date. The aim of the present study was to evaluate the efficacy and safety of zonisamide in the treatment of adult Chinese patients with refractory partial-onset epilepsy... CONCLUSION: Zonisamide 300-400 mg/day is effective and well tolerated as an adjunctive drug in adult Chinese patients with refractory partial-onset epilepsy.

more studies >>

Clinical Trials Related to Zonegran (Zonisamide)

Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial [Completed]
The primary objective of this study is to compare the efficacy of zonisamide (Zonegran;

100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who

have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.

Zonisamide for the Treatment of Obstructive Sleep Apnea in Overweight/Obese Patients [Completed]
This RCT explores the efficacy of Zonisamide (Zonegran«)on overweight/obese in patients with moderate to severe obstructive sleep apnea. Patients will be randomized to receive zonisamide, placebo or nasal continuous positive airway pressure (nCPAP) during 4 weeks. A 5 month open extension part will follow when patients in the tablet groups will all receive zonisamide. Patients in the open CPAP group will continue with CPAP treatment. Study hypothesis: Controlled pharmacological weight reduction with Zonisamide will result in elimination of OSA and OSA sequels more effectively than nCPAP due to incomplete compliance with the mechanical treatment and a lack of direct beneficial metabolic effects after nCPAP. Further it is hypothesized that zonisamide has a direct pharmacological effect on respiratory control during sleep by its carbonic anhydrase inhibitory effects and this will result in a reduction of sleep disordered breathing.

Zonegran in the Treatment of Binge Eating Disorder Associated With Obesity [Completed]
The specific aim of this study is to examine the efficacy and safety of zonisamide compared with placebo in outpatients with binge eating disorder associated with obesity.

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran« 100 mg Capsule after a single, one-capsule dose in fasted subjects.

Bioequivalence Study of Zonisamide Capsules 100 mg of Dr.Reddy's Laboratories Limited Under Fed Conditions [Completed]
The objective of this study was to compare the rate and extent of absorption of Dr. Reddy's Zonisamide 100 mg Capsule to that of Zonegran« 100 mg Capsule after a single, one-capsule dose in subjects fed a high standard fat meal.

more trials >>

Reports of Suspected Zonegran (Zonisamide) Side Effects

Rash (11)Convulsion (11)Agitation (8)Foetal Exposure During Pregnancy (6)Drug Interaction (6)Fatigue (6)Confusional State (5)Drug Ineffective (5)Chest Pain (5)Vomiting (5)more >>


Page last updated: 2016-06-15

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015